Magazine Article | November 7, 2018

Why A State Of Agility Continues To Elude Life Sciences R&D

Source: Life Science Leader

By James Man

In life sciences, improving organizational agility has been a strategic preoccupation for a long time now — particularly reducing R&D cycle times and accelerating market delivery. But the results have often been less than inspiring. The sticking point is the way companies make decisions. For sharper practices to produce tangible benefits to external stakeholders, pharmaceutical companies must also be smarter about the programs they deliver — able to determine and prioritize those that offer maximum value to their intended markets.

Yet few R&D organizations have the line of sight and dexterity to achieve this. Typically, strategic decision-making is held back by restrictive governance structures and functional silos and a lack of supporting market, patient, and regulatory evidence and insight at key investment points. Turning this situation around involves improving the integration, quality, and speed of decision- making across the R&D organization.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: